Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for receptor platelet- derived growth factor beta
Most Correlated Studies
- L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
- L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
- L1000 CMAP - Colorectal cancer HT29 cells treated with ligand perturbagens
- L1000 CMAP - Lung cancer A549 cells treated with ligand perturbagens
- L1000 CMAP - Amelanotic malignant melanoma of skin A375 cells treated with ligand perturbagens
Most Relevant Literature
- Establishment of extensive artificial intelligence models for kinase inhibitor prediction: Identific…
- Corneal Vascularization Associated With a Novel PDGFRB Variant.
- Concurrent PTEN and PDGFRB Alterations Characterize Storiform Collagenoma.
- High-Grade Sarcomas with Myogenic Differentiation Harboring Hotspot PDGFRB Mutations.
- The novel TERF2::PDGFRB fusion gene enhances tumorigenesis via PDGFRB/STAT5 signalling pathways and …
Most Relevant Clinical Trials
- Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activ…
- Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer…
- A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma
- A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors
- Italian Study Of Validation Of Angiogenesis Polymorphisms In HCC Patients Treated With Sorafenib
